Trent JF, Kirsner RS: Tissue engineered skin: Apligraf, a bi-layered living skin equivalent. .Int J Clin Pract 56::408. ,1998. .
Parenteau NL, Bilbo P, Nolte CJ, et al: The organotypic culture of human skin keratinocytes and fibroblasts to achieve form and function. .Cytotechnology 9::163. ,1992. .
Sabolinski ML, Alvarez O, Auletta M, et al: Cultured skin as a “smart material” for healing wounds: experience in venous ulcers. .Biomaterials 17::311. ,1996. .
Martin P: Wound healing: aiming for perfect skin regeneration. .Science 276::75. ,1997. .
Kerstein MD: The scientific basis of healing. .Adv Wound Care 10::30. ,1997. .
Lazarus GS, Cooper DM, Knighton DR, et al: Definitions and guidelines for assessment of wounds and evaluation of healing. .Arch Dermatol 130::489. ,1994. .
Cornwall JV, Dore CJ, Lewis JD: Leg ulcers: epidemiology and aetiology. .Br J Surg 73::693. ,1986. .
Nangia A, Gambhir R, Maibach H: Factors influencing the performance of temporary skin substitutes. .Clin Mater 7::3. ,1991. .
Tarlton JF, Bailey AJ, Crawford E, et al: Prognostic value of markers of collagen remodeling in venous ulcers. .Wound Repair Regen 7::347. ,1999. .
Falanga V, Margolis D, Alvarez O, et al: Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent: human skin equivalent investigators group. .Arch Dermatol 134::293. ,1998. .
Auger FA, Rouabhia M, Goulet F, et al: Tissue-engineered human skin substitutes developed from collagen-populated hydrated gels: clinical and fundamental applications. .Med Biol Eng Comput 36::801. ,1998. .
Laing P: The development and complications of diabetic foot ulcers. .Am J Surg 176 (suppl 2A)::11S. ,1998. .
Katz AB, Taichman LB: Epidermis as a secretory tissue: an in vitro tissue model to study keratinocyte secretion. .J Invest Dermatol 102::55. ,1994. .
Falanga V: Apligraf treatment of venous ulcers and other chronic wounds. .J Dermatol 25::812. ,1998. .
Angle N, Bergan JJ: Chronic venous ulcer. .BMJ 314::1019. ,1997. .
Allman RM: Pressure ulcer prevalence, incidence, risk factors, and impact. .Clin Geriatr Med 13::421. ,1997. .
Allman RM: Outcomes in prospective studies and clinical trials. .Adv Wound Care 8 (suppl)::61. ,1995. .
Brem H, Balledux J, Bloom T, et al: Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. .Arch Surg 135::627. ,2000. .
Ratliff CR, Rodeheaver GT: Pressure ulcer assessment and management. .Lippincotts Prim Care Pract 3::242. ,1999. .
Defloor T: The risk of pressure sores: a conceptual scheme. .J Clin Nurs 8::206. ,1999. .
Dolynchuk K, Hull P, Guenther L, et al: The role of Apligraf in the treatment of venous leg ulcers. .Ostomy Wound Manage 45::34. ,1999. .
Nelzen O, Bergqvist D, Lindhagen A, et al: Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. .J Epidemiol Community Health 45::184. ,1991. .
Boulton AJ, Meneses P, Ennis WJ: Diabetic foot ulcers: a framework for prevention and care. .Wound Rep Reg 7::7. ,1999. .
Daniels TR: Diabetic foot ulcerations: an overview. .Ostomy Wound Manage 44::76. ,1998. .
Levin M: Diabetic foot wounds: pathogenesis and management. .Adv Wound Care 10::24. ,1997. .
Pham HT, Rosenblum BI, Lyons TE, et al: Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. .Wounds 11::79. ,1999. .
Langemo DK: Venous ulcers: etiology and care of patients treated with human skin equivalent grafts. .J Vasc Nurs 17::6. ,1999. .
Rudolph DM: Pathophysiology and management of venous ulcers. .J Wound Ostomy Continence Nurs 25::248. ,1998. .
Black SB: Venous stasis ulcers: a review. .Ostomy Wound Manage 41::20. ,1995. .
Fitzpatrick JE: Stasis ulcers: update on a common geriatric problem. .Geriatrics 44::19. ,1989. .
Eaglstein W, Iriondo M, Laszlo K: A composite skin substitute (graftskin) for surgical wounds: a clinical experience. .Dermatol Surg 21::839. ,1995. .
Knight EV, Oldham JW, Mohler, MA, et al: A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB). .Am J Surg 176 (suppl 2A)::55S. ,1998. .
Skin grafting provides an effective means of closing chronic wounds. Autografts and allografts are used most often in skin grafting, but Apligraf, a tissue-engineered bilayered human skin equivalent, provides another safe and effective grafting option for treating diabetic, venous, and pressure ulcers. This skin equivalent has an epidermis and dermis similar to human skin, largely due to its derivation from neonatal foreskin. Apligraf is also easily accessible and has shown little immunoreactivity. (J Am Podiatr Med Assoc 92(1): 19-23, 2002)